Search Result

Results for "

butyrylcholinesterase (BChE)

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amyloid-β (2) Apoptosis (1) Cannabinoid Receptor (1) Cholinesterase (ChE) (42) Cytochrome P450 (1) Endogenous Metabolite (1) Histone Acetyltransferase (1) Isotope-Labeled Compounds (4) Keap1-Nrf2 (1) Monoamine Oxidase (2) NF-κB (1) Parasite (1) Reactive Oxygen Species (1)
By Research Areas:	Cancer (3) Cardiovascular Disease (1) Infection (2) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (41)

Inhibitors & Agonists

Fluorescent Dye

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-E70362

Butyrylcholinesterase (BCHE), Horse Serum BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl	Others	Others
Butyrylcholinesterase (BCHE), Horse Serum (BCHE, BuChE, PCHE, pseudocholinesterase, plasma cholinesterase, Acylcholine acyl-hydrolase, Choline esterase, butyryl) is a biological material or organic compound that can be used in life science research .

HY-135006

Octahydroaminoacridine succinate	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine succinate, a Tacrine analogue, is an acetylcholinesterse (AChE) and **butyrylcholinesterase (BChE)** inhibitor. Octahydroaminoacridine succinate can be used for Alzheimer's disease (AD) research .

HY-163883

BChE-IN-34	Cholinesterase (ChE)	Neurological Disease
BChE-IN-34 is a potent and selective **butyrylcholinesterase (BChE)** inhibitor with an IIC₅₀ of 25 nM. BChE-IN-34 shows excellent selectivity against BChE over acetylcholinesterase. BChE-IN-34 has neuroprotective and antioxidant effects .

HY-N7708

Lycodoline	Cholinesterase (ChE)	Neurological Disease
Lycodoline is a alkaloid with **butyrylcholinesterase (BChE) (IC₅₀** of 667 μM) inhibition activities .

HY-N10488

BChE-IN-11	Cholinesterase (ChE)	Neurological Disease
BChE-IN-11 (compound 10) is a potent, selective and non-competitive *BChE* (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-157982

BChE-IN-28	Cholinesterase (ChE)	Neurological Disease
BChE-IN-28 (compound 6J) is a selective **butyrylcholinesterase (BChE) inhibitor with an IC₅₀ of 8 nM and a K_i** of 12.16 nM. BChE-IN-28 shows the lower inhibition against AChE, MAO-A and MAO-B .

HY-N10489

BChE-IN-12	Cholinesterase (ChE)	Neurological Disease
BChE-IN-12 (compound 12) is a potent **butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀** value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Cholinesterase (ChE)	Neurological Disease
BChE-IN-10 (compound 6) is a potent **butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀** value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-135006A

Octahydroaminoacridine	Cholinesterase (ChE)	Neurological Disease
Octahydroaminoacridine, a Tacrine analogue, is an acetylcholinesterse (AChE) and **butyrylcholinesterase (BChE)** inhibitor. Octahydroaminoacridine can be used for Alzheimer's disease (AD) research .

HY-170389

BChE-IN-39	Cholinesterase (ChE)	Neurological Disease
BChE-IN-39 (Compound 7c) is an inhibitor for *butyrylcholinesterase* (BChE) with an IC₅₀ of 0.08 μM. (IC₅₀=3.98 μM for AChE) BChE-IN-39 downregulates the GSK-3β expression, inhibits the hyperphosphorylation of tau protein .

HY-151386

BChE-IN-13	Cholinesterase (ChE)	Neurological Disease
BChE-IN-13 (Compound 17c) is an orally active, potent and selective *Butyrylcholinesterase* (BChE) inhibitor with IC₅₀s of 0.22 and 0.016 μM for eqBChE and hBChE, respectively. BChE-IN-13 can improve memory and cognitive impairments, and be used in Alzheimer’s disease (AD) research .

HY-131971

AChE/BChE-IN-1	Cholinesterase (ChE)	Neurological Disease
AChE/BChE-IN-1 is a potent and brain-penetrant dual inhibitor of Acetylcholinesterase and *Butyrylcholinesterase, with IC₅₀s of 1.06 and 7.3 nM for hAChE* and hBChE, respectively. AChE/BChE-IN-1 also has antioxidant activity. AChE/BChE-IN-1 can be used for the research of Alzheimer’s disease .

HY-151389

BChE-IN-14	Cholinesterase (ChE)	Neurological Disease
BChE-IN-14 (compound 19c) is a selective *butyrylcholinesterase* (BChE) inhibitor with IC₅₀s of 0.23 and 0.011 μM for eqBChE and hBChE, respectively. BChE-IN-14 shows good blood brain barrier permeation and primary cell safety. BChE-IN-14 is able to restore cognitive impairment in vivo, it can be used for the research of Alzheimer’s disease .

HY-N2157

Pteryxin 1 Publications Verification (+)-Pteryxin	Cholinesterase (ChE)	Neurological Disease Metabolic Disease
Pteryxin, a coumarin in Peucedanum japonicum Thunb leaves, exerts antiobesity activity . Pteryxin is a potent **butyrylcholinesterase (BChE)** inhibitor, with an IC₅₀ of 12.96 μg/ml .

HY-122140

ACG548B	Cholinesterase (ChE)	Neurological Disease
ACG548B (compound 24) is a potent inhibitor of acetyl- and butyrylcholinesterase (AChE and *BChE) with IC₅₀s of 1.78 and 0.496 μM, respectively. ACG548B has higher AChE* affinity and selectivity over *BChE* and ChoK (choline kinase) .

HY-147859

BChE-IN-8	Amyloid-β	Neurological Disease
BChE-IN-8 (compound 20) is an orally active, potent and BBB-penetrated *BChE* (butyrylcholinesterase) inhibitor, with IC₅₀ values of 0.15 nM (eqBChE, equine serum BChE) and 45.2 nM (hBChE), respectively. High stability of BChE-IN-8 contributes to significantly improved blood concentration and tissue exposure. BChE-IN-8 can exert neuro-protecting and cognition improving properties through multiple modulations, including cholinergic system, Aβ aggregation, neuropeptide levels. BChE-IN-8 can be used for Alzheimer's disease (AD) research .

HY-159143

BChE-IN-33	Cholinesterase (ChE) Cytochrome P450	Neurological Disease
BChE-IN-33 (compound 4r), an arylaminonaphthol derivative, is a potent **butyrylcholinesterase (BChE) inhibitor with an IC₅₀** of 14.78 µM. BChE-IN-33 also inhibits CYP2C19, CYP2C9, CYP2D6. BChE-IN-33 shows potent antioxidant activity with IC₅₀ values of 150.48 μM, 2.56 μM and 4.61 μM by DPPH, ABTS, Ferric-phenanthroline assay, respectively. BChE-IN-33 has the potential for Alzheimer research .

HY-149993

hBChE-IN-2	Cholinesterase (ChE) Cannabinoid Receptor	Neurological Disease
hBChE-IN-2 (compound 15d) is a **butyrylcholinesterase (BChE) inhibitor (IC₅₀ of 0.62 μM) and a cannabinoid receptor 2 (CB2R)** agonist. hBChE-IN-2 has neuroprotection activities .

HY-N10490

Blestrin D	Cholinesterase (ChE)	Neurological Disease
Blestrin D is a potent **butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀** value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-162340

Z32439948	Cholinesterase (ChE)	Neurological Disease
Z32439948 is a butyrylcholinesterase (BChE) inhibitor (IC₅₀: 1.4 μM, hBChE) and is a derivative of m-sulfamoylbenzamide. Z32439948 also exhibited neuroprotective effects against glutamate in SH-SY5Y cells .

HY-121191

Bisnorcymserine N1,N8-Bisnorcymserine; (-)-Bisnorcymserine	Cholinesterase (ChE)	Neurological Disease
Bisnorcymserine ((-)-Bisnorcymserine) is an inhibitor for *butyrylcholinesterase* (BChE) with an IC₅₀ of 0.228 nM. Bisnorcymserine reduces the levels of amyloid-β peptide (Aβ), exhibits ameliorates the Alzheimer’s Disease in elderly rat models. Bisnorcymserine is blood-brain barrier penetrate .

HY-N10917

Xanthohumol I	Cholinesterase (ChE)	Infection Cancer
Xanthohumol I, a chalkone, is a derivative of Xanthohumol (HY-N1067). Xanthohumol is a Cholinesterase (ChE) inhibitor, which inhibits acetylcholinesterase (AChE) and **butyrylcholinesterase (BChE) wih IC₅₀s of 71.34 μM and 32.67 μM, respectively. The hydroxy compound of Xanthohumol (3-hydroxy-xanthohumol), also shoes inhibitory effect on AChE and BChE with IC₅₀**s of 51.25 μM and 63.07 μM .

HY-103373

PE154	Cholinesterase (ChE)	Neurological Disease
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and *butyrylcholinesterase* (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

HY-N12581

Kuwanon U	Cholinesterase (ChE)	Neurological Disease
Kuwanon U is a potent *cholinesterase* inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

HY-133776

Rivastigmine carbamate impurity 3-Nitrophenyl ethyl(methyl)carbamate	Cholinesterase (ChE)	Neurological Disease
Rivastigmine carbamate impurity (3-Nitrophenyl ethyl(methyl)carbamate) is an impurity of Rivastigmine. Rivastigmine is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively .

HY-157981

AChE-IN-60	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
AChE-IN-60 (compound 6k) is a potant acetylcholinesterase (AChE) and **butyrylcholinesterase (BChE) inhibitor with IC₅₀s of 27 nM and 43 nM, respectively. AChE-IN-60 also inhibits monoamine oxidase (MAO)-A and MAO-B with IC₅₀**s of 353 nM and 716 nM, respectively .

HY-157437

AChE/BChE-IN-16	Cholinesterase (ChE) Reactive Oxygen Species	Neurological Disease Inflammation/Immunology
AChE/BChE-IN-16 (compound C7) is a potent cholinesterase (ChE) inhibitor with IC₅₀s of 30 nM and 48 nM for human acetylcholinesterase (hAChE) and *human butyrylcholinesterase* (hBChE)*, respectively. AChE/BChE-IN-16 exhibits a remarkable capacity to safeguard PC12 cells against H₂O₂-induced apoptosis and effectively suppresses the production of reactive oxygen species (ROS)* .

HY-149300

SB-1436	Cholinesterase (ChE)	Neurological Disease
SB-1436 is an *Cholinesterase* (ChE) inhibitor, inhibits acetylcholinesterase (AChE), butyrylcholinesterase (BChE) and recombinant human acetylcholinesterase (rHuAChE) with IC₅₀s of 0.176, 0.37 and 0.08 μM, respectively. SB-1436 inhibits AChE and BChE in a non-competitive manner with K_is of 0.046 and 0.115 μM, respectively. SB-1436 significantly stops the self-aggregation of Aβ, and can be used for neurological disease research .

HY-144689

BChE-IN-3	Cholinesterase (ChE)	Neurological Disease
BChE-IN-3 (compound 45a) is a potent, selective, time-dependent and pseudoirreversible BChE inhibitor, with an IC₅₀ of 56.9 nM. BChE-IN-3 also shows marginal and reversible (not time-dependent) inhibition of AChE .

HY-N10781

Isograndifoliol	Cholinesterase (ChE)	Cardiovascular Disease Neurological Disease Cancer
Isograndifoliol is a selective inhibitor of *butyrylcholinesterase* (BChE) with an IC₅₀ value of 0.9 μM. And Isograndifoliol moderately inhibits acetylcholinesterase (AChE) with an IC₅₀ value of 342.9 μM. Isograndifoliol also has vasorelaxant effect and anti-tumor effect. Isograndifoliol can be used for research against dementia caused by neurodegenerative diseases .

HY-N6009

8-Deoxygartanin	Parasite NF-κB	Infection
8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of **butyrylcholinesterase (BChE)** . 8-Deoxygartanin exhibits antiplasmodial activity with an IC₅₀ of 11.8 μM for the W2 strain of Plasmodium falciparum . 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC₅₀ of 11.3 μM .

HY-161331

S16–1029	Cholinesterase (ChE)	Neurological Disease
S16–1029 is a selective and orally active **butyrylcholinesterase (BChE) inhibitor with IC₅₀**s of 11.35 nM and 48.1 nM for eqBChE and hBChE, respectively. S16–1029 could cross the blood-brain barrier (BBB) and reach the central nervous system (CNS). S16–1029 can be used for Alzheimer's disease (AD) research .

HY-17368

Rivastigmine 1 Publications Verification ENA 713 free base; SDZ-ENA 713 free base	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-11017

Rivastigmine tartrate 1 Publications Verification ENA 713; SDZ-ENA 713	Cholinesterase (ChE)	Neurological Disease
Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S1

(Rac)-Rivastigmine-d6 (Rac)-ENA 713-d₆ free base; (Rac)-SDZ-ENA 713-d₆ free base	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

HY-107569

Garcinol 1 Publications Verification	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite	Inflammation/Immunology Cancer
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards *acetyl cholinesterase* (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀** = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-W654336

(S)-Rivastigmine-d4	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride ENA 713-d₃ hydrochloride; SDZ-ENA 713-d₃ hydrochloride	Cholinesterase (ChE) Isotope-Labeled Compounds	Neurological Disease
Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368R

Rivastigmine (Standard) ENA 713 (free base)(Standard); SDZ-ENA 713 (free base)(Standard)	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (Standard) is the analytical standard of Rivastigmine. This product is intended for research and analytical applications. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-11017R

Rivastigmine (tartrate) (Standard) ENA 713 (Standard); SDZ-ENA 713 (Standard)	Cholinesterase (ChE)	Neurological Disease
Rivastigmine (tartrate) (Standard) is the analytical standard of Rivastigmine (tartrate). This product is intended for research and analytical applications. Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-161643

S21-1011	Cholinesterase (ChE) Keap1-Nrf2	Neurological Disease Inflammation/Immunology
S21-1011 is a selective inhibitor for butyrylcholinesterase (BChE), with IC₅₀ of 0.059 and 0.162 μM, for eqBChE and hBChE, respectively. S21-1011 exhibits good blood-brain barrier (BBB) permeability and good pharmacokinetic characters. S21-1011 exhibits anti-inflammatory activity through activation of keap1-Nrf2-ARE pathway (EC₅₀ is 23.48 μM for antioxidant element ARE activation), ameliorates cognitive impairment in murine Alzheimer’s disease model .

HY-168301

CL-13	Cholinesterase (ChE) Amyloid-β	Neurological Disease
CL-13 is a butyrylcholinesterase (BChE) inhibitor, with an IC₅₀ of 1.15 μM, and a selectivity index (SI) of 9.2 for acetylcholinesterase. CL-13 shows antioxidant activity in SH-SY5Y cells (DPPH EC₅₀ = 47.01 μM) and has the ability to chelate metals involved in Aβ aggregation and/or oxidative stress, showing no neurotoxicity at 50 μM. CL-13 can reverse cognitive impairment caused by scopolamine (HY-N0296) without affecting the mice's motor skills .

HY-W654335

Rivastigmine-d4 tartrate	Isotope-Labeled Compounds Cholinesterase (ChE)	Neurological Disease
Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits **butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀**s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W540232

4-Methoxyphenyl isothiocyanate 4-Methylphenyl ITC	Cholinesterase (ChE)	Neurological Disease
4-Methoxyphenyl isothiocyanate (4-Methylphenyl ITC) is an antioxidant, with a IC₅₀ value of 1.25 mM for scavenging DPPH radicals. ORAC testing indicates its antioxidant capacity as 11.7 mM TE (indicating that the antioxidant efficacy of this compound is equivalent to 11.7 mmol of Trolox (HY-101445, a standard antioxidant) under the same conditions), and it extends the oxidation process by approximately 9180 seconds in the Briggs–Rauscher reaction. Additionally, 4-Methoxyphenyl isothiocyanate exhibits moderate cholinesterase inhibitory activity, with an inhibition rate of 30.4% against acetylcholinesterase (AChE) and 17.9% against butyrylcholinesterase (BChE). 4-Methoxyphenyl isothiocyanate holds potential for research in the fields of antioxidation and neurological disorders .

HY-158978

Multitarget AD inhibitor-2	Cholinesterase (ChE) Monoamine Oxidase	Neurological Disease
Multitarget AD inhibitor-2 (Compound VN-19) is a multitargeting inhibitor acetylcholinesterase (AChE, IC₅₀=0.14 μM), butyrylcholinesterase (BChE, IC₅₀=11.6 μM), monoamine oxidase B (MAO B, IC₅₀=0.45 μM). Multitarget AD inhibitor-2 inhibits self-induced aggregation of amyloid beta protein Aβ1-42 (inhibition rate is 47.3% at 20 μM), and downregulates the level of ROS in SH-SY5Y (80 inhibition rate at 25 μM). Multitarget AD inhibitor-2 ameliorates the cognitive decline in Scopolamine (HY-N0296)-induced Alzheimer’s Disease zebrafish models .

Cat. No.	Product Name	Type

HY-103373

PE154	Fluorescent Dyes/Probes
PE154 (Compound 13) is a potent fluorescent inhibitor of human acetylcholinesterase (AChE) and *butyrylcholinesterase* (BChE) (IC₅₀s=280 pM and 16 nM, respectively) . PE154 can label β-amyloid plaques in histochemical analysis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N2157

Pteryxin 1 Publications Verification (+)-Pteryxin	Structural Classification Source classification Coumarins Phenylpropanoids Umbelliferae Plants Achillea atrata L.	Cholinesterase (ChE)
Pteryxin, a coumarin in Peucedanum japonicum Thunb leaves, exerts antiobesity activity . Pteryxin is a potent **butyrylcholinesterase (BChE)** inhibitor, with an IC₅₀ of 12.96 μg/ml .

HY-N6009

8-Deoxygartanin	Infection other families Xanthones Classification of Application Fields Source classification Phenols Polyphenols Plants Disease Research Fields	Parasite NF-κB
8-Deoxygartanin, a prenylated xanthones from G. mangostana, is a selective inhibitor of **butyrylcholinesterase (BChE)** . 8-Deoxygartanin exhibits antiplasmodial activity with an IC₅₀ of 11.8 μM for the W2 strain of Plasmodium falciparum . 8-Deoxygartanin inhibits NF-κB (p65) activation with an IC₅₀ of 11.3 μM .

HY-107569

Garcinol 1 Publications Verification	Structural Classification Classification of Application Fields Guttiferae Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields Garcinia indica	Cholinesterase (ChE) Histone Acetyltransferase Apoptosis Endogenous Metabolite
Garcinol, a polyisoprenylated benzophenone harvested from Garcinia indica, exerts anti-cholinesterase properties towards *acetyl cholinesterase* (AChE) and butyrylcholinesterase (BChE) with IC₅₀s of 0.66 µM and 7.39 µM, respectively . Garcinol also inhibits histone acetyltransferases (HATs, IC₅₀= 7 μM) and p300/CPB-associated factor (PCAF, IC₅₀** = 5 μM). Garcinol has anti-inflammatory and anti-cancer activity .

HY-N7708

Lycodoline	Lycopodiaceae Alkaloids Piperidine Alkaloids Structural Classification Source classification Plants Lycopodium japonicum Thunb. ex Murray	Cholinesterase (ChE)
Lycodoline is a alkaloid with **butyrylcholinesterase (BChE) (IC₅₀** of 667 μM) inhibition activities .

HY-N10488

BChE-IN-11	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-11 (compound 10) is a potent, selective and non-competitive *BChE* (butyrylcholinesterase) inhibitor, with an IC₅₀ of 2.1 μM. BChE-IN-11 can be used for Alzheimer's disease (AD) research .

HY-N10489

BChE-IN-12	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
BChE-IN-12 (compound 12) is a potent **butyrylcholinesterase (BChE) non-competitive inhibitor with an IC₅₀** value of 2.3 μM. BChE-IN-12 can be isolated from Bletilla striata. BChE-IN-12 can be used for the research of Alzheimer's disease (AD) .

HY-N10486

BChE-IN-10	Bletilla striata (Thunb. ex Murray) Rchb. f. Classification of Application Fields Neurological Disease Orchidaceae Source classification Phenols Polyphenols Plants Disease Research Fields	Cholinesterase (ChE)
BChE-IN-10 (compound 6) is a potent **butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀** value of 6.4 μM. BChE-IN-10 can be isolated from Bletilla striata. BChE-IN-10 can be used for the research of Alzheimer's disease (AD) .

HY-N10490

Blestrin D	Bletilla striata (Thunb. ex Murray) Rchb. f. Orchidaceae Source classification Polyphenols Plants	Cholinesterase (ChE)
Blestrin D is a potent **butyrylcholinesterase (BChE) mixed-type inhibitor with an IC₅₀** value of 8.1 μM. Blestrin D can be isolated from Bletilla striata. Blestrin D can be used for the research of Alzheimer's disease (AD) .

HY-N10917

Xanthohumol I	Structural Classification Humulus lupulus L. Source classification Phenols Polyphenols Plants Moraceae	Cholinesterase (ChE)
Xanthohumol I, a chalkone, is a derivative of Xanthohumol (HY-N1067). Xanthohumol is a Cholinesterase (ChE) inhibitor, which inhibits acetylcholinesterase (AChE) and **butyrylcholinesterase (BChE) wih IC₅₀s of 71.34 μM and 32.67 μM, respectively. The hydroxy compound of Xanthohumol (3-hydroxy-xanthohumol), also shoes inhibitory effect on AChE and BChE with IC₅₀**s of 51.25 μM and 63.07 μM .

HY-N12581

Kuwanon U	Structural Classification Flavonoids Flavonones Source classification Morus alba L. Plants Moraceae	Cholinesterase (ChE)
Kuwanon U is a potent *cholinesterase* inhibitor with IC₅₀s of 19.69, 10.11 µM and K_is of 6.48, 9.59 µM for acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), respectively. Kuwanon U has the potential for the research of Alzheimer’s disease (AD) .

Species:	Human (1) Mouse (1)
Tag:	His (2)
Source:	HEK293 (2)

Cat. No.	Compare	Product Name	Species	Source

HY-P72859

	Butyrylcholinesterase/BCHE Protein, Mouse (HEK293, His) Cholinesterase; Acylcholine acylhydrolase; Choline esterase II; BCHE	Mouse	HEK293
	Butyrylcholinesterase (BCHE) Protein, an esterase with broad substrate specificity, crucially inactivates acetylcholine, maintaining neurotransmitter homeostasis. Beyond acetylcholine metabolism, BCHE degrades neurotoxic organophosphates, highlighting its detoxification role. The enzyme's versatility underscores its critical function in safeguarding against harmful effects of neurotoxic compounds. Butyrylcholinesterase/BCHE Protein, Mouse (HEK293, His) is the recombinant mouse-derived Butyrylcholinesterase/BCHE protein, expressed by HEK293 , with C-His labeled tag. The total length of Butyrylcholinesterase/BCHE Protein, Mouse (HEK293, His) is 576 a.a., with molecular weight of 60-70 kDa.

HY-P7690

	Butyrylcholinesterase/BCHE Protein, Human (HEK293, His) rHuBCHE, His; Butyrylcholine Esterase; BCHE; Choline Esterase II	Human	HEK293
	Butyrylcholinesterase/BCHE Protein, Human (HEK293, His) is a recombinant human butyrylcholinesterase (BuChE) produced in HEK293 cells, with His tag. BuChE, one of cholinesterases, is a serine hydrolase closely related to acetylcholinesterase.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-17368S1

(Rac)-Rivastigmine-d6

(Rac)-Rivastigmine-d₆ is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease[1][2].

HY-W654336

(S)-Rivastigmine-d4

(S)-Rivastigmine-d₄ is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-17368S2

Rivastigmine-d3 hydrochloride

Rivastigmine-d₃ hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

HY-W654335

Rivastigmine-d4 tartrate

Rivastigmine-d₄ (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC₅₀s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease .

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P82715

	Butyrylcholinesterase Antibody (YA2460) BCHE; Butyrylcholine esterase; CHE1; CHE2; Choline esterase II; Cholinesterase (serum) 2; Cholinesterase 1; Cholinesterase; E1	WB	Human
	Butyrylcholinesterase Antibody (YA2460) is a biotin-conjugated non-conjugated IgG antibody, targeting Butyrylcholinesterase, with a predicted molecular weight of 68 kDa (observed band size: 90 kDa). Butyrylcholinesterase Antibody (YA2460) can be used for WB experiment in human background.